The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Credit: Arcutis. Zoryve topical foam is a once-daily steroid-free formulation of a highly potent and selective phosphodiesterase type 4 inhibitor. The Food and Drug Administration (FDA) has approved ...

In early May 2026, Arcutis Biotherapeutics reported first-quarter revenue of US$105.4 million, reduced its net loss to US$11.3 million, and reaffirmed full-year 2026 net product revenue guidance of ...

Zoryve cream 0.05% is available in a 60g tube. Zoryve ® (roflumilast) cream 0.05% is now available for the topical treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Approximately 1.8 million children aged 2 to 5 years are ...

Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company focused on developing innovations in immuno-dermatology, announced the U.S. Food and Drug Administration has approved the ...

Once-daily ZORYVE foam provides powerful clearance and rapid itch relief from head to toe with no limitation on duration of use More than half of the nearly 9 million people in the United States with ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...

Q1 2026 Management View "We’re very excited to have submitted a supplemental NDA for ZORYVE cream, 0.05% in atopic dermatitis patients aged 3 to 24 months in April" (President, CEO & Director Todd ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...